BRICS elevates traditional medicine with landmark declaration and new expert working group - World Health Organization (WHO)

HOUSTON — Chevron Chief Financial Officer Eimear Bonner will become president of its oil, products and gas business, the company said on Monday. Jeff Gustavson, currently president of Chevron’s new energies business, will succeed Bonner as CFO. Both moves are effective January 1. The executive reshuffle comes as the second-largest US oil major is preparing for CEO Mike Wirth to hand over the reins. In December, Wirth said he was in discussions with the board about succession planning and did not expect to serve more than 10 years in the role. Bonner and Gustavson are both seen as potential candidates for CEO, several investors have told Reuters. Wirth has led the company for more than eight years. Latest updates on company news here“Chevron maintains a robust succession planning process overseen by the board. We have strong leadership across the company and a deep bench of experienced executives prepared to lead the business,” a company spokesperson said. The oil major also said Mark Nelson, currently head of the oil, products and gas business, will leave the role on January 1 but remain vice chairman and oversee strategy and business development.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.